Cargando…

Anti-angiogenic therapy in ovarian cancer: Current understandings and prospects of precision medicine

Ovarian cancer (OC) remains the most fatal disease of gynecologic malignant tumors. Angiogenesis refers to the development of new vessels from pre-existing ones, which is responsible for supplying nutrients and removing metabolic waste. Although not yet completely understood, tumor vascularization i...

Descripción completa

Detalles Bibliográficos
Autores principales: Mei, Chao, Gong, Weijing, Wang, Xu, Lv, Yongning, Zhang, Yu, Wu, Sanlan, Zhu, Chunqi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027942/
https://www.ncbi.nlm.nih.gov/pubmed/36959862
http://dx.doi.org/10.3389/fphar.2023.1147717
_version_ 1784909825253048320
author Mei, Chao
Gong, Weijing
Wang, Xu
Lv, Yongning
Zhang, Yu
Wu, Sanlan
Zhu, Chunqi
author_facet Mei, Chao
Gong, Weijing
Wang, Xu
Lv, Yongning
Zhang, Yu
Wu, Sanlan
Zhu, Chunqi
author_sort Mei, Chao
collection PubMed
description Ovarian cancer (OC) remains the most fatal disease of gynecologic malignant tumors. Angiogenesis refers to the development of new vessels from pre-existing ones, which is responsible for supplying nutrients and removing metabolic waste. Although not yet completely understood, tumor vascularization is orchestrated by multiple secreted factors and signaling pathways. The most central proangiogenic signal, vascular endothelial growth factor (VEGF)/VEGFR signaling, is also the primary target of initial clinical anti-angiogenic effort. However, the efficiency of therapy has so far been modest due to the low response rate and rapidly emerging acquiring resistance. This review focused on the current understanding of the in-depth mechanisms of tumor angiogenesis, together with the newest reports of clinical trial outcomes and resistance mechanism of anti-angiogenic agents in OC. We also emphatically summarized and analyzed previously reported biomarkers and predictive models to describe the prospect of precision therapy of anti-angiogenic drugs in OC.
format Online
Article
Text
id pubmed-10027942
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100279422023-03-22 Anti-angiogenic therapy in ovarian cancer: Current understandings and prospects of precision medicine Mei, Chao Gong, Weijing Wang, Xu Lv, Yongning Zhang, Yu Wu, Sanlan Zhu, Chunqi Front Pharmacol Pharmacology Ovarian cancer (OC) remains the most fatal disease of gynecologic malignant tumors. Angiogenesis refers to the development of new vessels from pre-existing ones, which is responsible for supplying nutrients and removing metabolic waste. Although not yet completely understood, tumor vascularization is orchestrated by multiple secreted factors and signaling pathways. The most central proangiogenic signal, vascular endothelial growth factor (VEGF)/VEGFR signaling, is also the primary target of initial clinical anti-angiogenic effort. However, the efficiency of therapy has so far been modest due to the low response rate and rapidly emerging acquiring resistance. This review focused on the current understanding of the in-depth mechanisms of tumor angiogenesis, together with the newest reports of clinical trial outcomes and resistance mechanism of anti-angiogenic agents in OC. We also emphatically summarized and analyzed previously reported biomarkers and predictive models to describe the prospect of precision therapy of anti-angiogenic drugs in OC. Frontiers Media S.A. 2023-03-07 /pmc/articles/PMC10027942/ /pubmed/36959862 http://dx.doi.org/10.3389/fphar.2023.1147717 Text en Copyright © 2023 Mei, Gong, Wang, Lv, Zhang, Wu and Zhu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Mei, Chao
Gong, Weijing
Wang, Xu
Lv, Yongning
Zhang, Yu
Wu, Sanlan
Zhu, Chunqi
Anti-angiogenic therapy in ovarian cancer: Current understandings and prospects of precision medicine
title Anti-angiogenic therapy in ovarian cancer: Current understandings and prospects of precision medicine
title_full Anti-angiogenic therapy in ovarian cancer: Current understandings and prospects of precision medicine
title_fullStr Anti-angiogenic therapy in ovarian cancer: Current understandings and prospects of precision medicine
title_full_unstemmed Anti-angiogenic therapy in ovarian cancer: Current understandings and prospects of precision medicine
title_short Anti-angiogenic therapy in ovarian cancer: Current understandings and prospects of precision medicine
title_sort anti-angiogenic therapy in ovarian cancer: current understandings and prospects of precision medicine
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027942/
https://www.ncbi.nlm.nih.gov/pubmed/36959862
http://dx.doi.org/10.3389/fphar.2023.1147717
work_keys_str_mv AT meichao antiangiogenictherapyinovariancancercurrentunderstandingsandprospectsofprecisionmedicine
AT gongweijing antiangiogenictherapyinovariancancercurrentunderstandingsandprospectsofprecisionmedicine
AT wangxu antiangiogenictherapyinovariancancercurrentunderstandingsandprospectsofprecisionmedicine
AT lvyongning antiangiogenictherapyinovariancancercurrentunderstandingsandprospectsofprecisionmedicine
AT zhangyu antiangiogenictherapyinovariancancercurrentunderstandingsandprospectsofprecisionmedicine
AT wusanlan antiangiogenictherapyinovariancancercurrentunderstandingsandprospectsofprecisionmedicine
AT zhuchunqi antiangiogenictherapyinovariancancercurrentunderstandingsandprospectsofprecisionmedicine